What is Medtronic acquiring from CathWorks?

Medtronic is acquiring CathWorks, adding its FFRangio System, a non-invasive technology for evaluating coronary artery disease, to its heart devices portfolio.

How much is Medtronic paying for CathWorks?

The deal for CathWorks is valued at up to $585 million.

When is the Medtronic CathWorks acquisition expected to be completed?

The acquisition is expected to be completed by the end of Medtronic's fiscal year 2026, pending clearance from the U.S. Federal Trade Commission.

Home / Business and Economy / Medtronic Buys CathWorks for $585M Heart Tech Boost

Medtronic Buys CathWorks for $585M Heart Tech Boost

3 Feb

•

Summary

Medtronic is acquiring CathWorks for up to $585 million.
The deal adds non-invasive coronary artery disease diagnostic technology.
Acquisition is expected to be completed by fiscal year 2026.

Medtronic Buys CathWorks for $585M Heart Tech Boost

Medtronic announced its intention to purchase CathWorks, a privately held company, in a transaction valued up to $585 million. This strategic acquisition aims to bolster Medtronic's extensive portfolio of heart devices.

The deal will integrate the CathWorks FFRangio System, a cutting-edge non-invasive technology utilized for the diagnosis and assessment of coronary artery disease. This condition is a prevalent heart ailment characterized by plaque buildup restricting blood flow.

This move follows a partnership established between the two companies in 2022. The acquisition is subject to clearance from the U.S. Federal Trade Commission and is projected to finalize by the conclusion of Medtronic's fiscal year 2026.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.